Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

In the article by Schjesvold et al., entitled “Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis”, which appeared in the April 2021 issue of Haematologica (volume 106, pages 1182-1187), the values entered for “Refractory status” at the bottom of Table 1 were incorrect. The authors have prepared a new, corrected version of Table 1, which is reported here. The authors apologize to the Editor and readers for their mistake. They want to underscore that the results and conclusions of the paper are unaffected by the error.

Table 1.Patients’ baseline characteristics at study entry by age group in the intent-to-treat population.